The Association of Clinical Research Professionals (ACRP) has responded to the editors of The Toronto Star in regard to its recent news and editorial coverage of Health Canada and the pharmaceutical industry in Canada.
The Association of Clinical Research Professionals (ACRP) has responded to the editors of The Toronto Star in regard to its recent news and editorial coverage of Health Canada and the pharmaceutical industry in Canada. The letter takes issue with the way the news coverage mischaracterizes and sensationalizes Health Canada's relationship with pharmaceutical companies. In addition, ACRP's Deputy Executive Director Terri Hinkley, maintains that its "inaccurate picture for the public that unnecessarily and irresponsibly cultivates distrust, discourages trial participation, and by default casts an underserved shadow on the thousands of dedicated professionals, fellow Canadians, who conduct clinical trials responsibly and ethically."
Soon after the article was published, other Canadian clinical trials experts aired their own opinions of the Star's portrayal.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.